Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study
- 1 December 2006
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 20 (12) , 1309-1314
- https://doi.org/10.1002/bmc.697
Abstract
A new, simple, and reproducible method for determination of carboxylic acid metabolite of clopidogrel in human plasma has been developed. After liquid–liquid extraction in acidic medium with chloroform, samples were quantified on a Nova‐pak C8, 5 mm column using a mixture of 30 mm K2HPO4–THF–acetonitrile (pH = 3, 79:2:19, v/v/v) as mobile phase with UV detection at 220 nm. The flow rate was set at 0.9 mL/min. Ticlopidine was used as internal standard and the total run time of analysis was about 12 min. The method was linear over the range of 0.2–10 µg/mL of clopidogrel metabolite in plasma (r2 > 0.999). The within‐day and between‐day precision values were in the range 1.0–4.8%. The limit of quantification of the method was 0.2 µg/mL. The method was successfully used to study the pharmacokinetics of clopidogrel in healthy volunteers. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 7 references indexed in Scilit:
- Determination of clopidogrel metabolite (SR26334) in human plasma by LC–MSJournal of Pharmaceutical and Biomedical Analysis, 2006
- Estimation of carboxylic acid metabolite of clopidogrel in Wistar rat plasma by HPLC and its application to a pharmacokinetic studyJournal of Chromatography B, 2005
- The Metabolism of Clopidogrel Is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by AtorvastatinDrug Metabolism and Disposition, 2003
- Structure and Stereochemistry of the Active Metabolite of ClopidogrelDrug Metabolism and Disposition, 2002
- Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapyJournal of the American College of Cardiology, 2000
- ClopidogrelDrugs, 2000
- Clopidogrel, A Novel Antiplatelet and Antithrombotic AgentCardiovascular Drug Reviews, 1993